JP2022544227A5 - - Google Patents

Info

Publication number
JP2022544227A5
JP2022544227A5 JP2022508480A JP2022508480A JP2022544227A5 JP 2022544227 A5 JP2022544227 A5 JP 2022544227A5 JP 2022508480 A JP2022508480 A JP 2022508480A JP 2022508480 A JP2022508480 A JP 2022508480A JP 2022544227 A5 JP2022544227 A5 JP 2022544227A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
antibody
cancer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022508480A
Other languages
English (en)
Japanese (ja)
Other versions
JP7657774B2 (ja
JP2022544227A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/045567 external-priority patent/WO2021030240A1/en
Publication of JP2022544227A publication Critical patent/JP2022544227A/ja
Publication of JP2022544227A5 publication Critical patent/JP2022544227A5/ja
Priority to JP2025051867A priority Critical patent/JP2025106332A/ja
Application granted granted Critical
Publication of JP7657774B2 publication Critical patent/JP7657774B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022508480A 2019-08-13 2020-08-10 １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）による癌の治療方法 Active JP7657774B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025051867A JP2025106332A (ja) 2019-08-13 2025-03-26 １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）による癌の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886270P 2019-08-13 2019-08-13
US62/886,270 2019-08-13
PCT/US2020/045567 WO2021030240A1 (en) 2019-08-13 2020-08-10 Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025051867A Division JP2025106332A (ja) 2019-08-13 2025-03-26 １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）による癌の治療方法

Publications (3)

Publication Number Publication Date
JP2022544227A JP2022544227A (ja) 2022-10-17
JP2022544227A5 true JP2022544227A5 (https=) 2023-08-16
JP7657774B2 JP7657774B2 (ja) 2025-04-07

Family

ID=74569853

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022508480A Active JP7657774B2 (ja) 2019-08-13 2020-08-10 １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）による癌の治療方法
JP2025051867A Withdrawn JP2025106332A (ja) 2019-08-13 2025-03-26 １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）による癌の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025051867A Withdrawn JP2025106332A (ja) 2019-08-13 2025-03-26 １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）による癌の治療方法

Country Status (13)

Country Link
US (1) US20230001005A1 (https=)
EP (1) EP4013795A4 (https=)
JP (2) JP7657774B2 (https=)
KR (1) KR20220054321A (https=)
CN (1) CN114901690A (https=)
AU (1) AU2020329761A1 (https=)
BR (1) BR112022002391A2 (https=)
CA (1) CA3150274A1 (https=)
IL (1) IL290391A (https=)
MX (1) MX2022001731A (https=)
PH (1) PH12022550318A1 (https=)
TW (2) TW202540197A (https=)
WO (1) WO2021030240A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019392090A1 (en) 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
EP4143344A1 (en) * 2020-04-27 2023-03-08 Agendia N.V. Treatment of her2 negative, mammaprint high risk 2 breast cancer
IL302006A (en) * 2020-10-11 2023-06-01 Agensys Inc Methods for treating cancer with antibody-drug conjugates (ADC) that bind to proteins 191P4D12
EP4301774A4 (en) * 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2024012536A1 (zh) * 2022-07-14 2024-01-18 百奥泰生物制药股份有限公司 抗Nectin-4抗体、其抗体药物偶联物及应用
JP2026508244A (ja) 2023-02-22 2026-03-10 ナンジング リーズ バイオラブズ シーオー．， エルティーディー． 抗Ｎｅｃｔｉｎ－４抗体及びそれを含む多重特異性抗体
KR20250057677A (ko) * 2023-10-19 2025-04-29 (주)셀트리온 캄프토테신 유도체를 포함하는 항-Nectin-4 항체-약물 접합체

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX347954B (es) * 2010-09-29 2017-05-19 Agensys Inc Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
WO2012068279A2 (en) * 2010-11-16 2012-05-24 InnerGeo LLC System and method for extracting energy
JP2018521019A (ja) * 2015-06-08 2018-08-02 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体を使用して癌を治療する方法
BR112019002405A2 (pt) * 2016-08-26 2019-06-04 Hydril Usa Distrib Llc conjunto de transdutor para riser de perfuração offshore
AU2019392090A1 (en) * 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022544227A5 (https=)
JP2021059564A (ja) 癌治療のための併用療法
JP2022513684A5 (https=)
JP2021501776A5 (https=)
JP2021515017A5 (https=)
JP2021521143A5 (https=)
JP2024133544A5 (https=)
IL312038A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2021523233A5 (https=)
JP2021518394A5 (https=)
JP2021523158A5 (https=)
JP2022541591A5 (https=)
JP2022513386A5 (https=)
JP2021534165A5 (https=)
JP2025501978A5 (https=)
JP2023500888A5 (https=)
CN118201613A (zh) 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
CN116370641A (zh) 用于治疗消化系统恶性肿瘤的联用药物
JP2025501885A (ja) 抗ｔｒｏｐ－２抗体薬物複合体と他の治療薬との併用
JP2023519807A5 (https=)
JP2024506708A5 (https=)
JP2024536383A5 (https=)
CN116209443A (zh) 治疗小细胞肺癌的药物组合
WO2022033585A1 (zh) 用于治疗软组织肉瘤的联用药物
TW202545570A (zh) 抗體藥物偶聯物和免疫檢查點抑制劑的聯合應用